Weight-loss treatments are on the cusp of a revolution, and could benefit large numbers of Indians after the main patent ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

Global pharma giant Eli Lilly plans to launch its diabetes and obesity treatment, tirzepatide, marketed under the brands Mounjaro and Zepbound, in India by 2025. The proposed dosages ranged from 2.5 ...

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

Authorized generics are the exact copies of branded drugs, sold by another company with the branded drug manufacturer’s ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...